In our Monday pre market newsletter, Flight Path, we highlighted the healthcare sector as showing signs of outperformance. We talked about PFE, MRNAand the less popular NVAZ. Novavax is still in…
In our Monday pre market newsletter, Flight Path, we highlighted the healthcare sector as showing signs of outperformance. We talked about PFE, MRNAand the less popular NVAZ. Novavax is still in…